C型慢性肝炎治療の新たなストラテジー

出版社： 先端医学社
著者：
発行日： 2004-03-15
分野： 臨床医学：内科  >  肝/胆/膵
ISBN： 488407114X
電子書籍版： 2004-03-15 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,170 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,585 円(税込)

購入する

商品紹介

本書では、変貌をとげるＣ型慢性肝炎の治療に焦点をしぼり、現状と今後の展望について掲げている。Ｃ型慢性肝炎の研究および診療に必携の一冊。

目次

  • Ｃ型慢性肝炎治療の新たなストラテジー

    ―目次―

    PART１　Ｃ型慢性肝炎の診断と治療
    PART２　Ｃ型慢性肝炎の治療戦略とインターフェロン適応の根拠
    PART３　合併症を有するＣ型慢性肝炎の治療戦略
    PART４　Ｃ型慢性肝炎における新たな試み
    PART５　新しいアプローチによるＣ型慢性肝炎治療の今後

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

PART 1 C型慢性肝炎の診断と治療

P.23 掲載の参考文献
1) Okanoue T, Itoh Y, Minami M et al:Interferon therapy lowers the rate of progression of hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage:a retrospective study in 1148 patients. J Hepatol 30:653-659, 1999
 
2) Perry CM, Jarvis B:Peginterferon-alfa-2 a (40kD):a review of its use in the management of chronic hepatitis C. Drugs 61:2263-2288, 2001
PubMed
3) Heathcote EJ, Schiffman ML, Cooksley WG et al:Peginterferon alfa-2 a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343:1673-1680, 2000
 
4) Yasui K, Okanoue T, Murakami Y et al:Dynamics of hepatitis C viremia following interferon-alpha administration. J Infect Dis 177:1475-1479, 1998
PubMed
5) Neumann AU, Lam NP, Dahari H et al:Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107, 1998
PubMed
P.28 掲載の参考文献
1) 田中純子, 片山恵子, 熊谷純子ほか:供血者からみたHCV抗体陽性率, HBVキャリア率厚生労働省新興再興感染症研究事業 C型肝炎の自然経過および介入による影響等の評価を含む疫学的研究. 平成13年度報告書, 2002, pp. 62-68
 
2) Sasaki F, Tanaka J, Moriya T et al:Very low incidence rates of community-acquired hepatitis C virus infection in company employees, long-term inpatients, and blood donors in Japan. Epidemiol 6:198-203, 1996
PubMed
3) Moriya T, Sasaki F, Mizui M et al:Transmission of hepatitis C virus from mothers to infants:its frequency and risk factors revisited. Biomed Pharmacother 49:59-64, 1995
PubMed
4) 白木和夫, 飯塚俊之, 岡本学ほか:HCV母子感染およびHGV母子感染に関する研究厚生省非A非B型肝炎研究班. 平成8年度報告書, 1997, pp. 25-29
 
5) 田辺泰登, 佐々木富美子, 守屋尚ほか:覚醒剤 常用者におけるB型肝炎ウイルスおよびC型 肝炎ウイルスの感染状況についての検討. 肝臓 34:349, 1993
 
6) 吉澤浩司, 飯野四郎:ウイルス肝炎 診断/予防/治療 第2版, 文光堂, 東京, 2002, pp. 57-95
 
7) 吉澤浩司:C型肝炎検診の実施方法の確立に向けた検討 厚生労働省 21世紀型医療開拓推進事業 肝がん発生予防に資するC型肝炎検診の効果的な実施に関する研究班. 中間報告書, 2001
 
P.34 掲載の参考文献
1) Kimura M:Molecular evolutionary clock and the neutral theory. J Mol Evol 26:24-33, 1987
PubMed
2) Gojobori T, Moriyama EN, Kimura M:Molecular clock of viral evolution, and the neutral theory. Proc Natl Acad Sci USA 87:10015-10018, 1990
PubMed
3) Mizokami M, Gojobori T, Lau JY:Molecular evolutionary virology:its application to hepatitis C virus. Gastroenterology 107:1181-1182, 1994
PubMed
4) 溝上雅史, 折戸悦朗:肝炎ウイルスの分子進化. 日消病会誌 96:1033-1043, 1999
 
5) Ogata N, Alter HJ, Miller RH et al:Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 88:3392-3396, 1991
 
6) Pybus OG, Charleston MA, Gupta S et al:The epidemic behavior of the hepatitis C virus. Science 292:2323-2325, 2001
PubMed
7) Tanaka Y, Hanada K, Mizokami M et al:Inaugural Article:a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 99:15584-15589, 2002
 
8) El-Serag HB, Mason AC:Rising incidence of hepatocellular carcinoma in the United States.N Engl J Med 340:745-750, 1999
PubMed
9) Iida F, Iida R, Kamijo H et al:Chronic Japanese schistosomiasis and hepatocellular carcinoma:ten years of follow-up in Yamanashi Prefecture, Japan. Bull World Health Organ 77:573-581, 1999
PubMed
P.41 掲載の参考文献
1) Nakamura l, Imawari M:Cellular immulle response in HCV infection. J Gastroenterol 35:881-889, 2000
 
2) McGuirk P, Mills KH:Pathogen-specific regulatory T cells provoke a shift in the Th 1/Th 2 paradigm in immunity to infectious diseases. Trends Immunol 123:450-455, 2002
 
3) Lamonaca V, Missale G, Urbani S et al:Conserved hepatitis C virus sequences are highly immunogenic for CD 4+T cells:implications for vaccine development. Hepatology 30:1088-1098, 1999
 
4) Missale G, Cariani E, Lamonaca V et al:Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1 b-and genotype 2 c-infected patients. Hepatology 26:792-797, 1997
 
5) Kita H, Moriyama T, Kaneko T et al:A helper T-cell antigen enhances generation of hepatitis C virus-specific cytotoxic T lymphocytes in vitro. J Med Virol 45:386-391, 1995
 
6) Koziel MJ, Dudley D, Afdhal N et al:HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 96:2311-2321, 1995
 
7) He XS, Rehermann B, Lopez-Labrador FX et al:Quantitative analysis of hepatitis C virus-specific CD 8+ T cells in peripheral blood and liver using peptide-MHC tetralmers. Proc Natl Acad Sci USA 96:5692-5697, 1999
 
8) Ando K, Moriyama T, Guidotti LG et al:Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 178:1541-1554, 1993
 
9) Kondo T, Suda T, Fukuyama H et al:Essential roles of the Fas ligand in the development of hepatitis. Nat Med 3:409-413, 1997
PubMed
10) Nakamura I, Nupp JT, Cowlen M et al:Pathogenesis of experimental neonatal woodchuck hepatitis virus infection:chronicity as an outcome of infection is associated with diminished acute hepatitis that is temporally deficient for the expression of interferon gamma and tumor necrosis factor-alpha messenger RNAs. Hepatology 33:439-447, 2001
PubMed
11) Guidotti LG, Rochford R, Chung J et al:Viral Clearance without destruction of infected cells during acute HBV infection. Science 284:825-829, 1999
PubMed
12) Kanto T, Hayashi N, Takehara T et al:Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 162:5584-5591, 1999
PubMed
13) Bain C, Fatmi A, Zoulim F et al:Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120:512-524, 2001
PubMed
P.49 掲載の参考文献
1) Nagayama K, Kurosaki M, Enomoto N et al:Time-related changes in full-length hepatitis C virus sequences and hepatitis activity. Virology 263:244-253, 1999
PubMed
2) Nagayama K, Kurosaki M, Enomoto N et al:Characteristics of hepatitis C viral genome associated with disease progression. Hepatology 31:745-750, 2000
PubMed
3) Enomoto N, Sakuma I, Asahina Y et al:Mutations in the nonstructural protein 5 A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81, 1996
 
4) Enomoto N, Sakuma I, Asahina Y et al:Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96:224-230, 1995
PubMed
5) Watanabe H, Nagayama K, Enomoto N et al:Sequence elements correlated with circulating viral amounts in genotype 1b hepatitis C virus. Virology 311:376-383, 2003
 
6) Nagayama K, Enomoto N, Izumi N et al:Sequences in NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients. Gut 48:830-835, 2001
PubMed
7) Tanabe Y, Nagayama K, Enomoto N et al:Characteristic sequence changes of hepatitis C virus genotype 2 b associated with sustained biochemical response to IFN therapy. (submission)
 
8) Lohmann V, Korner F, Koch J et al:Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113, 1999
 
P.57 掲載の参考文献
1) Simmonds P, Alberti A, Alter HJ et al:A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321-1324, 1994
 
2) Okamoto H, Sugiyama Y, Okada S et al:Typing hepatitis C virus by polymerase chain reaction with type-specific primers:application to clinical surveys and tracing infectious sources. J Gen Virol 73:673-679, 1992
PubMed
3) Chayama K, Tsubota A, Arase Y et al:Genotypic subtyping of hepatitis C virus. J Gastroenterol 8:150-156, 1993
 
4) Tanaka T, Tsukiyama-Kohara K, Yamaguchi K et al:Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 19:1347-1353, 1994
 
5) Tanaka E, Kiyosawa K, Matsushima T et al:Epidemiology of genotypes of hepatitis C virus in Japanese patients with type C chronic liver diseases:a multi-institution analysis. J Gastroenterol Hepatol 10:538-545, 1995
PubMed
6) Aoyagi K, Ohue C, Iida K et al:Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 37:1802-1808, 1999
PubMed
7) Tanaka E, Ohue C, Aoyagi K et al:Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 32:388-393, 2000
PubMed
8) Enomoto N, Sakuma I, Asahina Y et al:Mutations in the nonstructural protein 5 A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81, 199657
 
P.62 掲載の参考文献
1) Ide T, Kumashiro R, Toyoda N et al:Second generation amplicor-HCV monitor assay:clinical features and predictors of the response to interferon. Hepatol Res 18:230-238, 2000
PubMed
2) 神代龍吉, 井出達也, 佐田通夫ほか:C型慢性肝炎に対するrIFNα-2a (ロフェロンA) 6か月投与における効果影響因子の検討. 消化器科 32:414-424, 2001
 
3) Jessner W, Gschwantler M, Steindl-Munda P et al:Primary interferon resistance and treatment response in chronic hepatitis C infection:a pilot study. Lancet 358:1241-1242, 2001
PubMed
4) Carlsson T, Weiland O, Reichard O:Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin. Scand J Gastroenterol 37:1228-1234, 2002
PubMed
P.67 掲載の参考文献
1) Tremolada F, Casarin C, Alberti A et al:Long-term follow-up of non-A, non-B (type C) post transfusion hepatitis. J Hepatol 16:273-281, 1992
 
2) Ikeda K, Saitoh S, Suzuki Y et al:Disease progression and hepatocellular carcinogenesis in patient with chronic viral hepatitis:a prospective observation of 2215 patients. J Hepatol 28:930-938, 1998
PubMed
3) Yoshida H, Shiratori Y, Moriyama M et al:Interferon therapy reduces the risk for hepatocellular carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. J Ann Intern Med 131:174-181, 1999
 
4) 吉澤浩司, 飯野四郎編:ウイルス肝炎 診断/予防/治療 第2版, 文光堂, 東京, 2002, p. 49
 
5) Reichard O, Norkrans G, Fryden A et al:Randomized, double-blind, placebo-controlled trial of interferon alpha-2 b with and without ribavirin for chronic hepatitis C. Lancet 351:83-87, 1998
 
6) McHutchison JG, Gordon SC, Schiff ER et al:Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485-1492, 1998
PubMed
7) Poynard T, Marcellin P, Lee SS et al:Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432, 1998
PubMed
8) Davis GL, Esteban-Mur R, Rustgi V et al:Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339:1493-1499, 1998
PubMed
9) Tong MJ, Reddy KR, Lee WM et al:Treatment of chronic hepatitis C with consensus interferon:a multicenter, randomized, controlled trial. Hepatology 26:747-754, 1997
PubMed
10) Suzuki H, Tango T:A multicenter, randomized, controlled clinical trial of interferon alfacon-l in comparison with lymphblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection. Hepatol Res 22:1-12, 2002
 
11) 熊田博光:IFN長期投与の効果:The Proceedings of The 23rd Inuyama Symposium, B 型・C型肝炎治療の新たな展開. 犬山シンポジウム記録刊行会編, アークメディア, 東京, 2002, pp. 155-158
 
12) Zeuzem S, Feinman SV, Rasenack J et al:Peginterferon alfa-2 a in patients with chronic hepatitis C. N Engl J Med 343:1666-1672, 2000
PubMed
13) Heathcote EJ, Shiffman ML, Cooksley WG et al:Peginterferon alfa-2 a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343:1673-1680, 2000
PubMed
P.74 掲載の参考文献
1) 市田文弘, 小俣政男, 辻孝夫ほか:慢性肝炎の肝組織診断基準-新犬山分類. 第19回記録"C型肝炎, 肝炎ウイルス, 犬山分類の再検討", 中外医学社, 東京, 1996, pp. 183-188
 
2) Desmet VJ, Gerber M, Hoofnagle JH et al:Classification of chronic hepatitis:diagnosis, grading and staging. Hepatology 19:1513-1520, 1994
 
3) 山田剛太郎:慢性肝炎の活動性と進行度の評価の標準化. 肝・胆・膵 45:349-355, 2002
 
4) Kobayashi M, Tanaka E, Sodeyama T et al:The natural course of chronic hepatitis C:a comparison between patients with genotype 1 and 2 hepatitis C viruses. Hepatology 23:695-699, 1996
PubMed
5) Mahmood S, Sho M, Yasuhara Y et al:Clinical significance of intrahepatic interleukin-8 in chronic hepatitis C patients. Hepatol Res 24:413-419, 2002
PubMed
6) Takahashi M, Yamada G, Miyamoto R et al:Natural course of chronic hepatitis C. Am J Gastroenterol 88:240-243, 1993
PubMed
7) Yano M, Kumada H, Kage M et al:The long-term pathological evolution of chronic hepatitis C. Hepatology 23:1334-1340, 1996
 
8) Poynard T, Bedossa P, Opolon P et al:Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349:825-832, 1997
PubMed
9) Yoshida H, Shiratori Y, Moriyama M et al:Interferon therapy reduces the risk for hepatocellular carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131:174-181, 1999
PubMed
10) 山田剛太郎:慢性肝炎の新しい組織分類. 日消病会誌 96:377-384, 1999
 
11) 山田剛太郎, 新山豪一, 川中美和:C型慢性肝炎におけるIFN治療の長期予後と効果不十分例の対策. 高度進行肝細胞癌, 生体肝部分移植, B型・C型慢性肝炎治療. 犬山シンポジウム記録刊行会編, 中外医学社, 東京, 2000, pp. 195-201
 

PART 2 C型慢性肝炎の治療戦略とインターフェロン適応の根拠

P.85 掲載の参考文献
1) Yoshida H, Shiratori Y, Moriyama M et al:Interferon therapy reduces the risk for hepatocellular carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131:174-181, 1999
PubMed
2) Tanaka H, Tsukuma H, Kasahara A et al:Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C:a retrospective cohort study of 738 patients. Int J Cancer 87:741-749, 2000
 
3) Kasahara A, Hayashi N, Mochizuki K et al:Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 27:1394-1402, 1998
PubMed
4) Imai Y, Kawata S, Tamura S et al:Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 129:94-99, 1998
PubMed
5) Ikeda K, Saitoh S, Arase Y et al:Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C:along-term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29:1124-1130, 1999
 
6) Camma C, Giunta M, Andreone P et al:Interferon and prevention of hepatocellular carcinoma in viral cirrhosis:an evidencebased approach. J Hepatol 34:593-602, 2001
PubMed
7) Valla DC, Chevallier M, Marcellin P et al:Treatment of hepatitis C virus-related cirrhosis:a randomized, controlled trial of interferon alfa-2 b versus no treatment. Hepatology 29:1870-1875, 1999
PubMed
8) Nishiguchi S, Shiomi S, Nakatalli S et al:Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357:196-197, 2001
 
9) Serfaty L, Aumaitre H, Chazouilleres O et al:Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 27:1435-1440, 1998
PubMed
10) Benvegnu L, Chemello L, Noventa F et al:Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 83:901-909, 1998
 
11) Niederau C, Lange S, Heilltges T et al:Prognosis of chronic hepatitis C:results of a large prospective cohort study. Hepatology 28:1687-1695, 1998
 
12) Yoshida H, Arakawa Y, Sata M et al:Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 123:483-491, 2002
PubMed
P.90 掲載の参考文献
1) 田中榮司:第II章C型肝炎, 1. 病態, 診断法, 予後, 自然経過と感染予防. コンセンサス肝疾患 2002 診断・治療と病態, 矢野右人, 林紀夫, 沖田極編, 日本メディカルセンター, 東京, 2002, pp. 114-123
 
2) 伊藤義人, 岡上武:C型慢性肝炎のインターフェロン治療はF2での肝癌発生を抑制するが, F3, F4では有意に抑制しない. 消化器科 26:87-92, 1997
 
3) 吉田晴彦, 白鳥康史, 小俣政男:インターフェロン療法の治療効果:長期予後. 肝・胆・膵 43:885-891, 2001
Medical*Online
4) Marcellin P, Asselah T, Boyer N:Fibrosis and disease progression in hepatitis C. Hepatology 36 (suppl 1):S47-S 56, 2002
 
5) Fontana RJ, Lok AS:Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 36 (suppl 1):S57-S 64, 2002
 
6) 笠原彰紀:第II章C型肝炎, 2. 治療, IFN治療 (1). コンセンサス肝疾患2002診断・治療と病態, 矢野右人, 林紀夫, 沖田極編, 日本メディカルセンター, 東京, 2002, pp. 124-135
 
7) Dienstag JL:The role of liver biopsy ill chronic hepatitis C. Hepatology 36 (suppl 1):S 152-S160, 2002
 
8) Desmet VJ, Gerber M, Hoofnagle JH et al:Classification of chronic hepatitis:diagnosis, grading and staging. Hepatology, 19:1513-1520, 1994
 
9) 市田文弘, 小俣政男, 辻孝夫ほか:慢性肝炎の肝組織診断基準-新犬山分類. 第19回犬山シンポジウム記録"C型肝炎, 肝炎ウイルス, 犬山分類の再検討", 中外医学社, 東京, 1996, pp. 183-188
 
P.95 掲載の参考文献
1) Yoshida H, Shiratori Y, Moriyama M et al:Interferon therapy reduces the risk for he-patocellular carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131:174-181, 1999
 
2) Colombo M, de Franchis R, Del Ninno E et al:Hepatocellular carcinoma in Italian patients with cirrhosis. 2V Engl J Med 325:675-680, 1991
 
3) Shindo M, Ken A, Okuno T:Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer 85:1943-1950, 1999
PubMed
4) Ikeda K, Saitoh S, Arase Y et al:Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C:along-term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29:1124-1130, 1999
 
5) Kasahara A, Hayashi N, Mochizuki K et al:Risk factors for hepatocellular carcinoma and its incidence after interferon treatment ill patients with chronic hepatitis C. Hepatology 27:1394-1402, 1998
 
6) Okanoue T, Itoh Y, Minami M et al:Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage:a retrospective study in 1148 patients. J Hepatol 30:653-659, 1999
 
7) Omata M, Shiratori Y:Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. J Gastroenterol 15:E 134-E 140, 2000
 
P.101 掲載の参考文献
1) Imai Y, Kawata S, Tamura S et al:Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 129:94-99, 1998
PubMed
2) Yabuuchi I, Imai Y, Kawata S et al:Longterm responders without eradication of hepatitis C virus after interferon therapy:characterization of clinical profiles and incidence of hepatocellular carcinoma. Liver 20:290-295, 2000
PubMed
3) Kasahara A, Hayashi N, Mochizuki K et al:Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 27:1394-1402, 1998
PubMed
4) Yoshida H, Shiratori Y, Moriyama M et al:Interferon therapy reduces the risk for hepatocellular carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131:174-181, 1999
PubMed
5) Ikeda K, Satoh S, Arase Y et al:Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C:a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29:1124-1130, 1999
 
6) Okanoue T, Itoh Y, Minami M et al:Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage:a retrospective study of 1148 patients. J Hepatol 30:653-659, 1999
 
7) Tanaka H, Tsukuma H, Kasahara A et al:Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C:a retrospective cohort study of 738 patients. Int J Cancer 87:741-749, 2000
 
8) Niederau C, Lange S, Heintges T et al:Prognosis of chronic hepatitis C:results of a large, prospective cohort study. Hepatology 28:1687-1695, 1998
PubMed
9) Yoshida H, Arakawa Y, Sata M et al:Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 123:483-491, 2002
PubMed
10) Benvegnu L, Chemello L, Noventa F et al:Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 83:901-909, 1998
 
11) Valla DC, Chevallier M, Marcellin P et al:Treatment of hepatitis C virus-related cirrhosis:a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 29:1870-1875, 1999
PubMed
12) Serfaty L, Aumaitre H, Chazouilleres O et al:Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 27:1435-1440, 1998
PubMed
13) Nishiguchi S, Shiomi S, Nakatani S et al:Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357:196-197, 2001
 
P.107 掲載の参考文献
1) Nishiguchi S, Kuroki T, Nakatani S et al:Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051-1055, 1995
PubMed
2) Nishiguchi S, Shiomi S, Nakatani S et al:Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357:196-197, 2001
 
3) Yoshida H, Shiratori Y, Moriyama M et al:Interferon therapy reduces the risk for hepatocellular Carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131:174-181, 1999
PubMed
4) Yoshida H, Arakawa Y, Sata M et al:Interferon therapy prolonged life expectancy among chronic hepatitis patierts. Gastroenterology 123:483-491, 2002
 
5) Kubo S, Nishiguchi S, Hirohashi K et al:Influence of previous interferon therapy on recurrence after resection of hepatitis C virus-related hepatocellular carcinoma.Jpn J Cancer Res 92:59-66, 2001
 
6) Kubo S, Nishiguchi S, Hirohashi K et al:Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Ann Intern Med 134:963-967, 2001
 
7) Muto Y, Moriwaki H, Ninomiya M et al:Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 334:1561-1567, 1996
PubMed
8) Oka H, Yamamoto S, Kuroki T et al:Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 76:743-749, 1995
PubMed
9) Ikeda K, Arase Y, Saitoh S et al:Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228-232, 2000
PubMed
10) Shiratori Y, Shiina S, Teratani T et al:Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138:299-306, 2003
PubMed

PART 3 合併症を有するC型慢性肝炎の治療戦略

P.116 掲載の参考文献
1) Rostaing L, Chatelut E, Payeh JL et al:Pharmacokinetics of alpha IFN-2 b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal fuction. J Am Soc Nephrol 9:2344-2348, 1998
 
2) Izopet J, Rostaing L, Moussion F et al:High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 176:1614-1617, 1997
PubMed
3) Rostaing L, Izopet J, Baron E et al:Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 59:1426-1431, 1995
PubMed
4) GUrsoy M, GUr G, Arslan H et al:Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 8:70-77, 2001
PubMed
5) 飯野四郎:抗ウイルス薬リバビリンの薬理と副作用. 化の領域 18:843-850, 2002
 
6) Bruchfeld A, Lindahl K, Schvarcz R et al:Dosage of ribavirin in patients with hepatitis C should be based on renal fuction. Ther Drug Monit 24:701-708, 2002
 
7) Bruchfeld A, Stahle L, Andersson J et al:Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection. J Viral Hepat 8:287-292, 2001
PubMed
8) 飯野四郎:C型慢性肝炎に対するIFN長期投与に伴う問題点とその対策. Prog Med 12:2637-2640, 1992
 
9) 飯野四郎:インターフェロンの副作用. 厚生省 特定疾患難治性の肝炎調査研究班平成5年度研究報告, pp. 7-11
 
10) 飯野四郎:C型慢性肝炎例でのインターフェロンの副作用. 医のあゆみ 171:1017-1022, 1994
Medical*Online
11) 熊田博光:C型肝炎ウイルスによる肝外病変. 厚生省新興・再興感染症研究事業非A非B型 肝炎の臨床的総合研究. 平成11年度研究報告書, pp. 157-159
 
12) Cacoub P, Poynard T, Ghillani P et al:Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheztm 42:2204-2212, 1999
PubMed
13) Cacoub P, Renou C, Rosenthal E et al:Extrahepatic manifestations associated with hepatitis C virus infection.Medicine 79:47-56, 2000
PubMed
14) Polzien F, Schott P, Mihm S et al:Interferon-alpha treatment of hepatitis C virus-associated mixed Cryoglobulinemia. J Hepatol 27:63-71, 1997
PubMed
15) Cresta P, Musset L, Cacoub P et al:Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut 45:122-128, 1999
PubMed
16) Zuckerman E, Keren D, Slobodin G et al:Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 27:2172-2178, 2000
PubMed
17) Sarac E, Bastacky, Johnson Jp:Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection. Am J Kidney Dis 30:113-115, 1997
PubMed
18) Loustaud-Ratti V, Liozon E, Karaaslan H et al:Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection. Am J Med 113:516-519, 2002
PubMed
19) Garcia-Suarez J, Burgaleta C, Hernanz N et al:HCV-associated thrombocytopenia:clinical characteristic and platelet response after recombinant alpha 2 b-interferon therapy. Brit J Haematol 110:98-103, 2000
 
20) Rajan S, Liebman HA:Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol 68:202-209, 2001
PubMed
21) Zuckerman E, Keren D, Rozenbaum M et al:Hepatitis C virus-related arthritis:characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol 18:579-584, 2000
PubMed
22) el-Serag HB, Kunik M, Richardson P et al:Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 123:476-482, 2002
PubMed
23) Forton DM, Thomas HC, Murphy CA et al:Hepatitis C and cognitive inpairment in a cohort of patients with mild liver disease. Hepatology 35:433-439, 2002
 
24) Musselman DL, Lawson DH, Gumnick JF et al:Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344:961-966, 2001
PubMed
25) Kraus MR, Schafer A, Faller H et al:Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 16:1091-1099, 2002
PubMed
26) Hauser P, Khosla J, Aurora H et al:A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 7:942-947, 2002
PubMed
27) Schaefer M, Schmidt F, Folwaczlly C et al:Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 37:443-451, 2003
PubMed
28) Soriano V, Garcia-Samaniego J, Bravo R et al:Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 23:585-591, 1996
PubMed
29) Boldorini R, Vigano P, Monga G et al:Hepatic histology of patients with HIV infection and chronic hepatitis C treated with interferon. J Clin Pathol 50:735-740, 1997
PubMed
30) Causse X, Payen JL, Izopet J et al:Does HIV-infection influence the response of chronic hepatitis C to interferon treatment?J Hepatol 32:1003-1010, 2000
PubMed
31) Kuehne FC, Bethe U, Freedberg K et al:Treatment for hepatitis C virus in human immunodeficiency virus-infected patients:clinical benefits and cost-effectiveness. Arch Intern Med 162:2545-2556, 2002
PubMed
32) Bruno R, Sacchi P, Puoti M et al:HCV chronic hepatitis in patients with HIV:clinical management issues. Am J Gastroenterol 97:1598-1606, 2002
PubMed
P.122 掲載の参考文献
1) 輸血後ウイルス肝炎の現状1993-1995. 日本赤十字社. 輸血後肝炎の防止に関する特定研究班研究報告書, 1996, pp. 7-14
 
2) 岩野けい子, 三井健宏, 増子和郎ほか:皿液透析患者におけるHCV抗体の臨床的検討. 透析会誌 24:1249-1252, 1991
 
3) 秋葉隆, 川口良人, 黒田満彦ほか:日本の透析施設におけるHCV感染に関する実態調査. 透析会誌 27:77-82, 1994
 
4) 荒川泰行, 川村典夫, 大久保仁ほか:医療機関内におけるHCV感染と予防対策総論. 日臨 53:435-450, 1995
Medical*Online
5) Iwasaki Y, Esumi M, Hosokawa N et al:Occasional infection of hepatitis C virus occurring in haemodialysis units identified by serial monitoring of the virus infection. J Hosp Infect 45:54-61, 2000
PubMed
6) 中井滋, 新里高弘, 稲葉隆ほか:わが国の慢性透析療法の現況 (1999年12月31日現在).透析会誌 34:1-31, 2001
 
7) Nakayama E, Akiba T, Marumo F et al:Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 11:1896-1902, 2000
PubMed
8) 内原正勝, 泉並木, 酒井義法ほか:血液透析患者のC型慢性肝炎に対するインターフェロン (IFN) 治療-IFNα2bの体内動態を中心とした検討. 肝臓 36:175, 1995
 
9) 立花直樹, 赤穂伸二, 出浦正ほか:C型慢性肝炎に対しインターフェロン-β治療を行った血液透析患者の1例-IFN-β薬物動態の検討-. 透析会誌 33:61-67, 2000
 
10) 山口友明, 前素直, 千田佳子ほか:血液透析施行中のC型慢性肝炎患者におけるインターフェロンα注 (天然型) の血中濃度動態に関する症例報告. 日病薬誌 38:59-62, 2002
 
11) Huraib S, Iqbal A, Tanimu D et al:Sustained Virological and Histological Response with Pretransplant Interferon Therapy in Renal Transplant Patients with Chronic Viral Hepatitis C. Am J Nephrol 21:435-440, 2001
PubMed
12) 林春幸, 入江康文, 横関一雄ほか:維持血液透析患者の慢性C型肝炎に対するインターフェロン療法-15例の経験. 透析会誌 28:1143-1149, 1995
 
13) 佐藤千史, 清澤研道, 茶山一彰ほか:HCV肝炎のインターフェロンによる治療-第40回日本透析医学会シンポジウムより-. 透析会誌 29:265-270, 1996
 
14) Bruchfeld A, Stahle L, Anderson J et al:Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 8:287-292, 2001
 
15) 田中純子, 吉澤浩司, 片山恵子ほか:血液透析患者を対象としたHCV感染に関する前向き調査. 非A非B型肝炎の予防, 疫学に関する研究. 平成12年度報告書, 2001, pp. 61-64
 
16) Centers for Disease Control and Prevention:Recommendations for prevention and control of hepatitis C virus infection and HCV related chronic disease. 1998
 
P.128 掲載の参考文献
1) Cacoub P, Renou C, Rosenthal E et al:Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 79:47-56, 2000
 
2) Obermayer-Straub P, Manns MP:Hepatitis Cand D, retroviruses and autoimmune manifestations. J Autoimmun 16:275-285, 2001
 
3) Clifford BD, Donahue D, Smith L et al:High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 21:613-619, 1995
PubMed
4) Cassani F, Cataleta M, Valentini P et al:Serum autoantibodies in chronic hepatitis C:comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 26:561-566, 1997
PubMed
5) Klein R, Zanger UM, Berg T et al:Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP 2 D 6 and novel peptide epitopes. Clin Exp Immunol 118:290-297, 1999
 
6) Manns MP, Obermayer-Straub P:Viral induction of autoimmunity:mechanisms and examples ill hepatology. J Viral Hepat (suppl 2):42-47, 1997
 
7) Csepregi A, Nemesanszky E, Luettig B et al:LKM 3 autoantibodies in hepatitis C cirrhosis:a further phenomenon of the HCV-induced autoimmunity. Am J Gastroenterol 96:910-911, 2001
PubMed
8) Kammer AR, van der Burg SH, Grabscheid B el al:Molecular mimicry of human cytochrome P 450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 190:169-176, 1999
 
9) Muratori L, Parola M, Ripalti A et al:Liver/Kidney microsomal antibody type 1 target CYP 2 D 60n hepatocyte plasma membrane. Gut 46:553-561, 2000
 
10) Dickson RC:Clinical manifestations of hepatitis C. Clinical manifestations of hepatitis C. In:Clinics in liver disease No 3, W. B. Saunders, 1997, pp. 569-585
 
11) Gumber SC, Chopra S:Hepatitis C:a multifaceted disease. Ann Intern Med 123:615-620, 1995
PubMed
12) King PD, Mc Murray RW, Becherer PR et al:Sjogren:s syndrome without mixed cryoglobulinemia is not associated with hepatitis C virus infection. Am J Gastroenterol 89:1047-1050, 1994
 
13) Laskus T, Slusarczyk J:Autoimmune chronic active hepatitis developing after acute type B hepatitis. Dig Dis Sci 34:1294-1297, 1989
PubMed
14) Lofkowitch JH, Vento S, Garofano T et al:Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis:type 1 in susceptible individuals. Lancet 337:1183-1187, 1991
 
15) Berk L, Schalm SW, Heijtink RA:Severe chronic active hepatitis (autoimmune type) mimicked by coinfection of hepatitis C and human immunodeficiency viruses. Gut 32:1198-1200, 1991
PubMed
16) Hilzenrat N, Ziberman D, Klein T et al:Autoimmune hepatitis in a genetically susceptible patient:is it triggered by acute viral hepatitis A?Dig Dis Sci 44:1950-1952, 1999
 
17) Alvarez F, Berg PA, Bianchi FB et al:International Autoimmune Hepatitis Group Report:review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929-938, 1999
PubMed
18) Zeniya M, Aizawa Y, Watanabe F et al:HCV-marker-positive autoimmune-type chronic active hepatitis:a possible relation between HCV infection and liver autoreaction. Liver 14:206-212, 1994
PubMed
19) Vella FS, Orlando P, Attanasi F et al:Autoantibodies in chronic hepatitis C. Markers of autoimmunity or non-specific events? Recenti Prog Med 92:107-112, 2001
PubMed
20) Schiano TD, Te HS, Thomas RM et al:Results of steroid-based therapy for the hepatitis C-autoimmune hepatitis overlap syndrome. Am J Gastroenterol 96:2984-2991, 2001
PubMed
21) Lunel F, Cascoub P:Treatment of autoimmune and extra-hepatic manifestations of HCV infectioll. Ann Med Interne (Paris) 151:58-64, 2000
 
22) 銭谷幹男, 戸田剛太郎:自己免疫性肝炎 私はこう治療している-. 自己免疫性肝疾患 その治療の実際 . 辻孝夫, 大西三朗編, 日本医学館, 東京, 1999, pp. 118-123
 
23) Yoshikawa M, Toyohara M, Yamane Y et al:Disappearance of serum HCV-RNA after short-term prednisolone therapy in a patient with chronic hepatitis C associated with autoimmune hepatitis-like serological manifestations. J Gastroenterol 34:269-274, 1999
 
P.134 掲載の参考文献
1) Okanoue T, Sakamoto S, Itoh Y et al:Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25:283-291, 1996
PubMed
2) Dusheiko G:Side effects of alpha interferon in chronic hepatitis C. Hepatology 26 (suppl 1):S 112-S 121, 1997
 
3) Di Bisceglie AM, Hoofnagle JH:Optimal therapy of hepatitis C. Hepatology 36 (suppl 1):S 121-S 127, 2002
 
4) 林紀夫, 清澤研道, 岡上武:肝疾患診療におけるRecommendation. 第II章C型肝炎, 2. 治療. コンセンサス肝疾患 2002 診断・治療と病態, 矢野右人, 林紀夫, 沖田極編, 日本メディカルセンター, 東京, 2002, pp. 27-30
 
5) 笠原彰紀:第II章C型肝炎, 2. 治療, IFN治療 (1). コンセンサス肝疾患 2002 診断・治療と病態, 矢野右人, 林紀夫, 沖田極編, 日本メディカルセンター, 東京, 2002, pp. 124-135
 
6) Foster GR, Goldin DR, Thomas HC:Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 27:209-212, 1998
 
7) Zdilar D, Franco-Bronson K, Buchler N et al:Hepatitis C, interferon alfa, and depression. Hepatology 31:1207-1211, 2000
PubMed
8) Barrett S, Goh J, Coughlan B et al:The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort:spontaneous viral clearance and chronic HCV infection. Gut 49:423-430, 2001
 
9) 大坪天平, 宮岡等, 上島国利ほか:C型慢性肝炎患者のインターフェロン療法中にみられる抑うつ状態に関して前方視的研究-. 精神誌 99:101-127, 1997
 
10) Miyaoka H, Otsubo T, Kamijima K et al:Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 156:1120, 1999
PubMed
11) Van Thiel DH, Friedlander L, Molloy PJ et al:Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 7:165-168, 1995
PubMed
12) Pariante CM, Orru MG, Baita A et al:Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 354:131-132, 1999
 
13) Edlin BR, Seal KH, Lorvick J et al:Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?N Engl J Med 345:211-215 2001
PubMed
14) Pariante CM, Landau S, Carpiniello B:Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis. N Engl J Med 347:148-149, 2002
PubMed
15) Schaefer M, Schmidt F, Folwaczny C et al:Adherence and mental side effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups. Hepatology 37:443-451, 2003
PubMed
16) Dobmeier M, Frick E, Frank S et al:Schizo-phrenic psychosis:a contraindication for treatment of hepatitis C with interferon alpha? Pharmacopsychiatry 33:72-74, 2000
 
17) Fattovich G, Giustina G, Favarato S et al:A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 24:38-47, 1996
 
18) Valentine AD, Meyers CA, Kling MA et al:Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25 (suppl 1):39-47, 1998
 
19) Fingerhood MI, Jasinski DR, Sullivan JT:Prevalence of hepatitis C in a chemically dependent population. Arch Intern Med 153:2025-2030, 1993
 
20) Capuron L, Ravaud A:Prediction of thedepressive effects of interferon alpha therapyby the patient's initial affective state. N Engl J Med 340:1370, 1999
 
21) Fontana RJ, Hussain KB, Schwartz SM et al:Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol 36:401-407, 2002
 
22) 大坪天平:IFNによるうつ病. 肝・胆・膵 45:1063-1069, 2002
Medical*Online
23) McHutchison JG, Poynard T:Combinationtherapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 19 (suppl 1):57-65, 1999
 
24) Maddrey WC:Safety of combination interferon alfa-2b/ribavirin therapy in chronichepatitis C-relapsed and treatment-nativepatients. Semin Liver Dis (suppl 1) 19:67-75, 1999
 
25) Keeffe EB, Hollinger FB:Therapy of hepatitis C:consensus interferon trials. Hepatology 26 (suppl 1):101 S-107 S, 1997
 
26) Jones TH, Wadler S, Hupart KH:Endocrinemediated mechanisms of fatigue duringtreatment with interferon-alpha. Semin Oncol 25 (suppl 1):54-63, 1998
 
27) Meyers CA, Scheibel RS, Forman AD:Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 41:672-676, 1991
PubMed
28) Malaguarnera M, Di Fazio I, Restuccia S et al:Interferon alpha-induced depression inchronic hepatitis C patients:comparison between different types of interferon alpha. Neuropsychobiology 37:93-97, 1998
 
29) Kraus MR, Schafer A, Scheurlen M:Paroxetine for the prevention of depression inducedby interferon alfa. N Engl J Med 345:375-376, 2001
 
30) Musselman DL, Lawson DH, Gumnick JF et al:Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344:961-966, 2001
PubMed
P.142 掲載の参考文献
1) 林紀夫:C型慢性肝炎. 肝臓病学Clinical Science. 戸田剛太郎, 清澤研道, 沖田極ほか編, 医学書院, 東京, 1998, pp. 324-325
 
2) Matsumori A, Matoba Y, Sasayama S:Dilated cardiomyopathy associated with hepatitis C virus infection. Circulαtion 92:2519-2525, 1995
 
3) Matsumori A, Matoba Y, Nishio R et al:Detection of hepatitis C virus RNA from the heart of patients with hypertrophic cardiomyopathy. Biochem Biophys Res Commun 222:678-682, 1996
PubMed
4) Matsumori A, Ohashi N, Hasegawa K et al:Hepatitis C virus infection and heart diseases:a multicenter study in Japan.Jpn Circ J 62:389-391, 1998
PubMed
5) 丸山茂雄, 平山千里:C型肝炎の肝外病変;心筋障害. 肝臓 42 (suppl 1):A140, 2001
 
6) Matsumori A:Hepatitis C virus and cardiomyopathy. Herz 25:249-254, 2000
PubMed
7) Matsumori A, Yutani C, Ikeda Y et al:Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest 80:1137-1142, 2000
PubMed
8) 島田俊夫ほか:C型肝炎ウイルスによる潜在する心筋障害とそれに及ぼすインターフェロン効果. 厚生省特定疾患特発性心筋症調査研究班平成10年度報告書, 1999, pp. 82-91
 
9) Sato Y, Takatsu Y, Yamada et al:Interferon treatment for dilated cardiomyopathy and striated myopathy associated with hepatitis C virus infection based on serial measurements of serum concentrations of cardiac troponin T. Jpn Circ J 64:321-324, 2000
PubMed
10) 福本真也, 石村栄治, 西沢良記ほか:インターフェロンアルファにより心筋症様心機能低下をきたしたクリオグロブリン血症の1例. 診断と治療 84 (suppl):830, 1996
Medical*Online
11) 片山和宏, 大前篤, 林紀夫:インターフェロンアルファにより心室性頻拍症をきたしたC型慢性肝炎の1例. 診断と治療 84 (suppl):772, 1996
Medical*Online
12) 塩埼道明, 竹田喜信, 中島周三ほか:インターフェロンアルファー2b治療1週間後に急性虫垂炎が出現し, 再治療でWenkebach型II度AVblockの誘発をみた1例. 診断と治療 84 (suppl):774, 1996
 
P.148 掲載の参考文献
1) Benhamou Y, Bochet M, Di Martino V et al:Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 30:1054-1058, 1999
PubMed
2) Amarapurkar D:Natural history of hepatitis C virus infection. J Gastroenterol Hepat 15 (Suppl):E 105-E 110, 2000
 
3) Bica I, McGovern B, Dhar R et al:Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32:429-497, 2001
 
4) Mohsen AH, Easterbrook PJ, Taylor C et al:Impact of human immunodeficiency virus (HIV) infection on the progression of Iiver fibrosis in hepatitis C virus infected patients. Gut 52:1035-1040, 2003
 
5) Law WP, Dore GJ, Duncombe CJ et al:Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 17:2191-2199, 2003
 
6) 菊地嘉, 中島由紀子, 矢崎博久ほか:HIV及び HCV合併感染血友病に対するインターフェロン療法. 第49回日本感染症学会東日本地方会総会, 2000
 
7) 菊地嘉, 塚田訓久, 照屋勝治ほか:HIV合併慢性C型肝炎に対するInterferon+Ribavirin治療. 厚生科学研究費補助金エイズ対策研究事業平成12年度報告書, 2001, pp. 141-147
 
8) 菊地嘉, 矢崎博久, 塚田訓久ほか:HIV合併慢性C型肝炎に対するInterferon+Ribavirin治療-続報-. 厚生科学研究費補助金エイズ対策研究事業平成13年度報告書, 2002, pp. 160-167
 
9) 菊地嘉, 矢崎博久, 本田美和子ほか:血友病 HIV感染者に合併したC型肝炎のPegylated Interferonα2a と ribavirinの治療成績. 厚生科学研究費補助金エイズ対策研究事業平成14年度報告書, 2003, pp. 148-155
 
P.154 掲載の参考文献
1) 飯野四郎, 小池満:肝炎ウイルスと悪性リンパ腫. 日臨 58:554-559, 2000
Medical*Online
2) Vallisa D, Berte R, Rocca A et al:Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course. Am J Med 106:556-560, 1999
PubMed
3) Izumi T, Sasaki R, Miura Y et al:Primary hepatosplenic lymphoma:association with hepatitis C virus infection. Blood 87:5380-5381, 1996
PubMed
4) Ferri C, La Civita L, Monti M et al:Can type C hepatitis infection be complicated by malignant lymphoma? Lancet 346:1426-1427, 1995
PubMed
5) Ohsawa M, Shingu N, Miwa H et al:Risk of non-Hodgkin's lymphoma in patients with hepatitis C virus infection. Int J Cancer 80:237-239, 1999
PubMed
6) McDonnell TJ, Korsmeyer SJ:Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t (14;18) . Nature 349:254-256, 1991
 
7) Ray RB, Meyer K, Ray R:Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 226:176-182, 1996
PubMed
8) Fanidi A, Harrington EA, Evan GI:Cooperative interaction between c-myc and bcl-2 Proto-oncogenes. Nature 359:554-556, 1992
PubMed
9) 広田雄一, 前田基, 柴田昌一郎ほか:心機能低下・warfarin内服・慢性C型肝炎合併の悪性リンパ腫に対しPBSCTを安全に施行した一例. 臨血 37:1099, 1996
 
10) 張高明, 石黒卓朗:HLA完全一致同胞ドナーからのPBSCT/BMTを実施したHCV, MRSA carrierのAML (M 2) の1例. 新潟医会誌 111:484, 1997
Medical*Online
11) 小宮英明, 山本浩文, 石井幸司ほか:治療中, HCVによると思われる一過性肝機能障害を認めた非Hodgkinリンパ腫の1例. 臨血 41:230, 2000
 
12) 川野千鶴, 室井一男, 菅野直子ほか:HCVRNA陽性ドナーより同種骨髄移植を行った慢性骨髄性白血病. 日輸血会誌 46:271, 2000
 
13) 一井倫子, 畑中一生, 玉置俊治ほか:高齢者の治療抵抗性2次性悪性リンパ腫に対してHCV陽性同胞からmini-transplantを施行し, 完全寛解を得た1例. 臨血 42:1079, 2001
 
14) 福神浩兼, 峯徹哉, 田嶋章弘ほか:白血病悪性リンパ腫に対して骨髄移植を行った慢性C型肝炎に対するインターフェロン治療. 日消病会誌 91 (臨時増刊号):691, 1994
 
P.160 掲載の参考文献
1) Arao M, Murase K, Kusakabe A et al:Prevalence of diabetes mellitus among Japanese patients infected chronically with hepatitis C virus.J Gastroenterol 38:355-36, 2003
PubMed
2) Maello T, Okumura A, Ishikawa T et al:Elevated serum levels of tumor necrosis factor α (TNFα) mediate increased insulin resistance in non-cirrhotic patients with chronic IICV infection. J Gastroenterol Hepatol (in press):2003
 
3) 笹岡利安:インターフェロン治療による耐糖能異常. 日臨 60:760-764, 2002
Medical*Online
4) 関孝一, 伊藤芳晴, 西泰雄ほか:C型慢性活動性肝炎のInterferon治療と眼底出血. 肝臓 34:385-391, 1993
 
5) 老籾宗忠, 坂井誠, 岩谷逸平:インターフェロンの副作用とその対策 (4) 糖代謝異常. 臨消内科 10:383-390, 1995
 
P.167 掲載の参考文献
1) Hijikata M, Mishiro S, Miyamoto C et al:Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients:revisited by analyzing two SNPsites (-123 and-88) in vivo and in vitro. Intervirology 44:379-382, 2001
 
2) Mochida S, Ohnishi K, Matsuo S et al:Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcohol Clin Exp Res 20:371 A-377 A, 1996
 
3) Yoshida H, Shiratori Y, Moriyama M et al:Interferon therapy reduces the risk for hepatocellular carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131:174-181, 1999
PubMed
4) C型肝炎に起因する肝がんの撲滅を目指して. (社) 日本肝臓学会, 2001
 
5) Okanoue T, Sakamoto S, Itoh Y et al:Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25:283-291, 1996
PubMed
6) Dusheiko G:Side effects of alpha interferonin chronic hepatitis C. Hepatology 26 (suppl 1):112 S-121 S, 1997
 
7) Fujiwara K, Mochida S, Matsuo S et al:Randomized control trial of interferon-betainjections at 12-h intervals as a therapy for chronic hepatitis C. Hepatol Res (suppl 1):240-251, 1998
 
8) Asahina Y, Izumi N, Uchihara M et al:A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. Hepatology 34:377-384, 2001
PubMed
9) Fujimori K, Mochida S, Matsui A et al:Possible mechanisms of elevation of serum transaminase levels during interferon-betatherapy in chronic hepatitis C patients. J Gastroenterol 37:40-46, 2002
 
10) 豊田成司, 我妻重彦, 安田清美ほか:インターフェロン無効または再燃したC型慢性肝炎に対するインターフェロンα-2bとSCH 18908 (リバビリン) の併用投与とインターフェロンα-2b単独投与の比較:二重盲検群間比較法を用いた併用効果の検討. 臨医薬 18:539-563, 2002
 
11) 飯野四郎, 松嶋喬, 熊田博光ほか:Genotype 1bかつ高ウイルス量のC型慢性肝炎に対するインターフェロンα-2bとSCH 18908 (リバビリン) の併用投与とインターフェロンα-2b単独投与の比較:二重盲検群間比較法を用いた用法・用量の検討. 臨医薬 18:565-591, 2002
 

PART 4 C型慢性肝炎における新たな試み

P.174 掲載の参考文献
1) McHutchison JG, Gordon SC, Schiff ER et al:Interferon alpha-2 b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485-1492, 1998
PubMed
2) Poynard T, Marcellin P, Lee SS et al:Randomised trial of interferon alpha 2 b plusribavirin for 48 weeks or for 24 weeks versusinterferon alfa 2 b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432, 1998
 
3) Davis GL, Esteban-Mur R, Rustgi V et al:Interferon alpha-2 b alone or in combination with ribavirin for the treatment or relapse of chronic hepatitis C. N Engl J Med 339:1493-1499, 1998
 
4) Zeuzem S, Feinman SV, Rasenack J et al:Peginterferon alfa-2 a in patients with chronic hepatitis C. N Engl J Med 343:1666-1672, 2000
PubMed
5) Manns MP, McHutchison JG, Gordon SC etal:Peginterferon alfa-2 b plus ribavirincompared with interferon alfa-2 b plus ribavirin for initial treatment of chronic hepatitis C:a randomized trial. Lancet 358:958-965, 2001
 
6) Fried MW, Shiffman ML, Reddy KR et al:Peginterferon alfa-2 a plus ribavirin forchronic hepatitis C virus infection. N Engl J Med 347:975-982, 2002
 
7) Kasahara A, Hayashi N, Hiramatsu N et al:Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C:a multicenter randomized controlled trial. Hepatology 21:291-297, 1995
PubMed
P.182 掲載の参考文献
1) Kasahara A, Hayashi N, Hiramatsu N et al:Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C:a multicenter randomized controlled trial. Hepatology 21:291-297, 1995
PubMed
2) Poynard T, Bedossa P, Chevallier M et al:A comparison of three interferon alfa-2 bregimens for the long-term treatment ofchronic non-A, non-B hepatitis. N Engl J Med 332:1457-1462, 1995
 
3) Reichard O, Foberg U, Fryden A et al:Highsustained response rate and clearance ofviremia in chronic hepatitis C after treatment with interferon-alpha 2 b for 60 weeks. Hepatology 19:280-285, 1994
 
4) Saracco G, Borghesio E, Mesina P et al:Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha 2 b for chronic hepatitis type C. J Hepatol 27:56-62, 1997
 
5) Arase Y, Suzuki Y, Kobayashi M et al:Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load. J Gastroenterol 38:158-163, 2003
PubMed
6) Arase Y, Tsubota A, Saitoh S et al:Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load. Hepatol Res 25:364-370, 2003
PubMed
7) Arase Y, Ikeda K, Chayama K et al:Randomized controlled clinical trial of lymphoblastoid interferon-alpha for chronic hepatitis C. Hepatol Res 21:55-66, 2001
PubMed
P.189 掲載の参考文献
1) Sidwell RW, Huffman JH, Khare GP et al:Broad-spectrum antiviral activity of Virazor:1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide. Science 177:705-706, 1972
PubMed
2) Ptterson JL, Felnandez-Larsson R:Molecular mecanisms of action of rivabirin. Rev Infect Dis 12:1132-1146, 1990
 
3) Cramp ME, Rossol S, Chokshi S et al:Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118:346-355, 2000
PubMed
4) Yee LJ, Tang J, Gibson AW et al:Interleukin 10 polymorphism as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology:33:708-712, 2001
PubMed
5) Di Bisceglie AM, Shindo M, Fong TL et al:Apilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16:649-654, 1992
 
6) Bondenheimer HC Jr, Lindsay KL, Davis GL et al:Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C:a multicenter trial. Hepatology 26:473-477, 1997
 
7) Brillanti S, Garson J, Foli M et al:A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107:812-817, 1994
PubMed
8) Lai MY, Kao JH, Yang PM et al:Longterm efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterolog 111:1307-1312, 1996
 
9) Reichard O, Norkrans G, Fryden A et al:Randomized double-blind, placebo-controlled trial of interferon alpha-2 b with and without ribavirin for chronic hepatitis C. Lancet 351:83-87, 1998
 
10) McHutchison JG, Gordon SC, Schiff ER et al:Interferon alfa-2 b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485-1492, 1998
PubMed
11) Poynard T, Marcellin P, Lee SS et al:Randomised trial of Interferon alpha-2 b plusribavirin for 48 weeks or for 24 weeks versusinterferon alpha 2 b plus placebo for 48 weeksfor treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432, 1998
 
12) EASL international consensus conference on hepatitis C. Paris, 26-28 February 1999, Consensus Statement. European Association forthe Study of the Liver. J Hepatol 30:956-961, 1999
 
13) Pol S, Nalpas B, Bourliere M et al:Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone inpatients with genotype-1b-related chronichepatitis C. Hepatology 31:1338-1344, 2000
 
14) Enriquez J, Gallego A, Torras X et al:Retreatment for 24 vs 48 weeks with interferon alfa-2 b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond tointerferon alone. J Viral Hepat 7:403-408, 2000
PubMed
15) Di Bisceglie AM, Thompson J, Smith-Wilkaitis N et al:Combination of interferon and ribavirin in chronic hepatitis C:re-treatment of nonresponders to interferon. Hepatology 33:704-707, 2001
PubMed
16) Kakumu S, Yoshioka K, Wakita T et al:Apilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 105:507-512, 1993
 
17) 飯野四郎, 松嶋喬, 楠正ほか:Genotype 1bかつ高ウイルス量のC型慢性肝炎に対するインターフェロンα-2bとSCH 18908 (リバビリン) の併用投与とインターフェロンα-2b単独投与との比較-二重盲検群間比較法を用いた用法・用量の検討-. 臨医薬 18:565-591, 2002
 
18) 豊田成司, 妻神重彦, 楠正ほか:インターフェロン無効または再燃したC型慢性肝炎に対するインターフェロンα-2bとSCH 18908 (リバビリン) の併用投与とインターフェロンα-2 b単独投与との比較-二重盲検群間比較法を用いた併用効果の検討-. 臨医薬 18:539-563, 2002
 
19) Kanto T, Hayashi N, Takehara T et al:Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 162:5584-5591, 1999
PubMed
20) Kamal SM, Fehr J, Roesler B et al:Peginterferon alone or with ribavirin enhances HCV-specific CD 4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 123:1070-1083, 2002
PubMed
21) Contreras AM, Hiasa Y, He W et al:Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 76:8505-8517, 2002
 
22) Mita E, Hayashi N, Hagiwara H et al:Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 39:977-982, 1994
PubMed
23) Tsubota A, Chayama K, Ikeda K et al:Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19:1088-1094, 1994
 
24) Enomoto N, Sakuma I, Asahina Y et al:Mutations in the nonstructual protein 5 Agene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81, 1996
 
25) Kasahara A, Hayashi N, Hiramatsu N et al:Ability of prolonged interferon treatment to suppress relapse after cessation of therapy with chronic hepatitis C:a multicenter randomized controlled trial. Hepatology 21:291-297, 1995
PubMed
26) Tsubota A, Akuta N, Suzuki F et al:Viral dynamics and pharmacokinetics in combined interferon alfa-2 b and ribavirin therapy for patients infected with hepatitis C virus ofgenotype 1b and high pretreatment viral load. 1ntervirology 45:33-42, 2002
 
27) 荒瀬康司, 坪田昭人, 熊田博光:インターフェロン+Ribavirin併用治療での治療効果とRibavirin血清濃度増加因子. 日消病会誌 100 (suppl):A99, 2003
 
28) 朝比奈靖浩, 泉並木, 三宅祥三:C型慢性肝炎に対するIFN/Ribavirin併用治療の治療効果とHCV遺伝子変異. 日消病会誌 100 (suppl):A99, 2003
 
29) 平松直樹, 考藤達哉, 林紀夫:C型慢性肝炎に対するIFN/Ribavirin併用治療における治療効果予測. 日消病会誌 100 (suppl):A98, 2003
 
P.196 掲載の参考文献
1) Wills RJ:Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19:390-399, 1990
 
2) Lam NP, Neumann AU, Gretch DR et al:Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26:226-231, 1997
PubMed
3) Xu ZX, Hoffman J, Patel I et al:Single-dose safety/tolerability and pharmacokinetic/ pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α2a (IFNα2a) to healthy subjects. Hepatology 28:702 A, 1998
 
4) Neumann AU, Lam NP, Dahari H et al:Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107, 1998
PubMed
5) 泉並木:C型肝炎-抗ウイルス療法の治療効果-リバビリン, PEG-IFNについて. 肝臓 43:436-441, 2002
 
6) Zeuzem S, Herrmann E, Lee JH et al:Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha 2 a. Gastroenterology 120:1438-1447, 2001
 
7) Zeuzem S, Feinman SV, Rasenack J et al:Peginterferon alfa-2 a in patients with chronic hepatitis C. N Engl J Med 343:1666-1672, 2000
PubMed
8) Heathcote EJ, Shiffman ML, Cooksley WG etal:Peginterferon alfa-2 a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343:1673-16802000
 
9) Buti M, Sanchez-Avila F, Lurie Y et al:Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2 b plus ribavirin. Hepatology 35:930-936, 2002
 
10) Lindsay KL, Trepo C, Heintges T et al:A randomized, double-blind trial comparing pegylated interferon alfa-2 b to interferonalfa-2 b as initial treatment for chronic hepatitis C. Hepatology 34:395-403, 2001
 
P.202 掲載の参考文献
1) Zeuzem S, Feinman SV, Rasenack J et al:Peginterferon alfa-2 a in patients with chronic hepatitis C. N Engl J Med 343:1666-1672, 2000
PubMed
2) Heathcote EJ, Shiffman ML, Cooksley WG et al:Peginterferon alfa-2 a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343:1673-1680, 2000
PubMed
3) Reddy KR, Wright TL, Pockros PJ et al:Efficacy and safety of pegylated (40-kd) interferon alpha-2 a compared with interferon alpha-2 a in noncirrhotic patients with chronic hepatitis C. Hepato logy 33:433-438, 2001
 
4) Lindsay KL, Trepo C, Heintges T et al:Arandomized, double-blind trial comparingpegylated interferon alfa-2 b to interferonalfa-2 b as initial treatment for chronic hepatitis C. Hepatology 34:395-403, 2001
 
5) Patterson JL, Fernandez-Larsson R:Molecular mechanisms of action of ribavirin. Rev Infect. Dis 12:1139-1146, 1990
PubMed
6) Cramp ME, Rossol S, Chokshi S et al:Hepatitis C virus-specific T-cell reactivity duringinterferon and ribavirin treatment in chronichepatitis C. Gastroenterology 118:346-355, 2000
 
7) Khakoo S, Glue P, Grellier L et al:Ribavirinand interferon alfa-2 b in chronic hepatitis C:assessment of possible pharmacokineticand pharmacodynamic interactions. Bl:J Clin Pharmacol 46:563-570, 1998
 
8) Tsubota A, Akuta N, Suzuki F et al:Viraldynamics and pharmacokinetics in combinedinterferon alpha-2 b and ribavirin therapy forpatients infected with hepatitis C virus of genotype 1b and high pretreatment viralload. Intervirology 45:33-42, 2002
 
9) Tsubota A, Hirose Y, Izumi N et al:Pharmacokineticsof ribavirin in combined interferon alpha 2 b and ribavirin therapy forchronic hepatitis C virus infection. Br J Clin Pharmacol 55:360-367, 2003
 
10) Fried MW, Shiffman ML, Reddy KR et al:Peginterferon alfa-2 a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982, 2002
PubMed
11) Glue P, Rouzier-Panis R, Raffanel C et al:A dose-ranging study of pegylated interferon alfa-2 b and ribavirin in chronic hepatitis C. Hepatology 32:647-653, 2000
PubMed
12) Manns MP, McHutchison JG, Gordon SC et al:Peginterferon alfa-2 b plus ribavirin compared with interferon alfa-2 b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial Lancet 358:958-965, 2001
 
P.209 掲載の参考文献
1) Blatt LM, Davis JM, Klein SB et al:The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 16:489-499, 1996
PubMed
2) Klein SB, Blatt LM, Taylor MW:Cell surface binding characteristics correlate with consensus type I interferon enhanced activity. J Interferon Cytokine Res 16:1-6, 1996
PubMed
3) Ozes ON, Reiter Z, Klein S et al:A comparison of interferon-Con 1 with natural recombinant interferon-alpha:antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res 12:55-59, 1992
 
4) Altrock BW, Fagin KD, Hockman HR et al:Antiviral and antitumor effects of a human interferon analog, IFN-alpha Con 1, assessed in hamsters. J Interferon Res 6:405-415, 1986
PubMed
5) 田中章平, 安田修平, 宮田桂司ほか:インターフェロンアルファコンー1 (YM 643) の腫瘍細胞増殖抑制作用および免疫増強作用. 薬理と臨 10:411-419, 2000
 
6) Yamano M, Yuki H, Yasuda S et al:Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM 643-induced depression-like behavior in mice. J Pharmaco Exp Ther 292:181-187, 2000
 
7) Suzuki H, Tango T:A multicenter, randomized, controlled clinical trial of interferon alfa con-1 in comparison with lymphoblastoid interferon-alpha in patients with hightiter chronic hepatitis C virus infection. Hepatol Res 22:1-12, 2002
 
8) Yoshioka K, Yano M, Hirofuji H et al:Randomized controlled trial of twice-a-day administration of natural interferon beta forchronic hepatitis C. Hepatol Res 18:310-319, 2000
 
9) Barbaro G, Barbarini G:Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2 b and ribavirin in combination:an Italian pilot study. Eur J Gastroenterol Hepatol 14:477-483, 2002
PubMed
10) Da Silva LC, Bassit L, Ono-Nita SK et al:High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin:a pilot study. J Gastroenterol 37:732-736, 2002
PubMed
P.215 掲載の参考文献
1) Davis GL, Esteban-Mur R, Rustgi V et al:Interferon alfa-2 b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339:1493-1499, 1998
PubMed
2) C型慢性肝炎患者395例を対象とした国内実施の臨床試験結果. http://medicalschering-plough.co.jp/hepatitis_c/index.html
 
3) Shiffman ML:Retreatment of patients with chronic hepatitis C. Hepatology 36 (5 Suppl 1) S 128-S 134, 2002
 
4) Heathcote EJ, Keeffe EB, Lee SS et al:Retreatment of chronic hepatitis C with consensus interferon. Hepatology 27:1136-1143, 1998
PubMed
5) Suzuki H, Consensus Interferon Research Group:A multicenter, open-label clinical trial of interferon alfacon-1 in patients with chronic hepatitis C virus infection who relapsed after initial interferon therapy.Jpn J Med Pharm Sci 46:215-224, 2001
 
6) Yokosuka O, Kato N, Hosoda K et al:Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA. Gut 37:721-726, 1995
PubMed
7) 沖田極, 熊田博光, 林紀夫:新しいC型慢性肝炎治療戦略. Medical Tribune 35:28-30, 2002
 
8) Arase Y, Ikeda K, Chayama K et al:Efficacy of IFN therapy based on duration period of negative HCV-RNA during IFN administration. Hepatol Res 19:22-30, 2001
 
9) Consensus statements on the prevention and management of hepatitis C in the Asia-Pacific region. Core working party for Asia-Pacific consensus on hepatitis B and C. J Gastroenterol Hepatol 15:825-841, 2000
 
10) EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. J Hepatol 30:956-961, 1999
PubMed
11) Booth JC, O:Grady J, Neuberger J:Clinical guidelines on the management of hepatitis C. Gut 49 (suppl 1):11-121, 2001
 
12) Jacobsen I:Pegylated interferon α-2 b plus ribavirin in patients with chronic C:a trial in prior nonresponder to interferon monotherapy or combination therapy and in combination therapy nonresponders. Gastroenterology 122:A 626, 2002
 
13) Shiffman ML:Retreatment of HCV non-responders with peginterferon and ribavirin:results from the lead-in phase of the hepatitis Cantiviral long term treatment against cirrhosls (HALT-C) trial. Hepatology 36 (abstract):295 A, 2002
 
14) Hinrichsen H:First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic hepatitis C genotype 1. Hepatology 36 (abstract):379 A, 2002
 
P.221 掲載の参考文献
1) Kasahara A, Hayashi N, Mochizuki K et al:Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 27:1394-1402, 1998
PubMed
2) Yoshida H, Shiratori Y, Moriyama M et al:Interferon therapy reduces the risk for hepatocellular carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern med 131:174-181, 1999
PubMed
3) Okanoue T, Itoh Y, Minami M et al:Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage:a retrospective study in 1148 patients. J Hepatol 30:653-659, 1999
 
4) Hino K, Kitase A, Satoh Y et al:Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat 9:370-376, 2002
PubMed
5) Toyoda H, Kumada T, Nakano S et al:The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinomain patients with chronic hepatitis C. Cancer 88:58-65, 2000
 
6) Tarao K, Rino Y, Ohkawa S et al:Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus associated cirrhosis. Cancer 86:589-595, 1999
PubMed
7) Ikeda K, Arase Y, Saitoh S et al:Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-a prospective randomized study of hepatitis C virus-relatedliver cancer. Hepatology 32:228-232, 2000
PubMed
8) Shiratori Y, Shiina S, Teratalli T et al:Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138:299-306, 2003
 
9) Murphy D, Detjen KM, Welzel M et al:Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 33:346-356, 2001
PubMed
10) Arase Y, Ikeda K, Murashima N et al:The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79:1494-1500, 1997
 
P.226 掲載の参考文献
1) 小俣政男:肝癌を視野に入れた肝炎の日常診療. 日本メディカルセンター, 東京, 1995
 
2) 日本肝臓学会:肝がん白書. http://www.jsh.or.jp/hakusho/top.html
 
3) 日本肝臓学会:慢性肝炎診療のためのガイドライン. http://www.jsh.or.jp/guide/guidemae.html
 
4) Yoshida H, Shiratori Y, Moriyama M et al:Interferon therapy reduces the risk for hepatocellular carcinoma:national Surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131:174-181, 1999
 
5) Yoshida H, Arakawa Y, Sata et al:Interferon theraphy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 123:483-491. 2002
 
P.231 掲載の参考文献
1) Shiffman ML, Stewart CA, Hofmann CM et al:Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels:comparison of hepatic histology and response to interferon therapy. J Infect Dis 182:1595-1601, 2000
PubMed
2) Jamal MM, Soni A, Quinn PG et al:Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 30:1307-1311, 1999
PubMed
3) Martinot-Peignoux M, Boyer N, Cazals-Hatem D et al:Prospective study on antihepatitis C virus-positive patients with persistently normal serum alanine transsaminase with or without detectable serum hepatitis C virus RNA. Hepatology 34:1000-1005, 2001
 
4) Persico M, Persico E, Suozzo R et al:Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 118:760-764, 2000
PubMed
5) Serfaty L, Chazouilleres O, Pawlotsky JM et al:Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 11O:291-295, 1996
 
6) Ideo G, Bellobuono A, Tempini S et al:Poor efficacy of alpha interferon in patients affected by chronic hepatitis C with normal or near normal ALT levels. Gastroenterology 110 (abstract):1215 A, 1996
 
7) San Giovanni A, Spinzl GC, Ceriani R et al:Randomized control trial of HCV healthy carriers with interferon. Hepatology 22 (abstract):290 A, 1995
 
8) Areias J, Pedroto I, Freitas T et al:Hepatitis C virus carriers with normal ALT activity:viremia, genotype and effect of interfer:on therapy. Gastroenterology 11O (abstract):1144A, 1996
 
9) Rossini A, Ravaggi A, Biasi L et al:Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. Hepatology 26:1012-1017, 1997
PubMed
10) Orito E, Mizokami M, Suzuki K et al:Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment. J Gastroenterol Hepatol 12:58-61, 1997
PubMed
11) Van Thiel DH, Caraceni P, Molloy PJ et al:Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels:the role of interferon alpha 2 b therapy. Hepatol 23:503-508, 1995
 
12) Yagura M, Murai S, Kojima H et al:Interferon treatment in patients with chronic hepatitis C with normal alanine-aminotransferaseactivity. Hepatogastroenterology 46:1094-1099, 1999
 
13) Gordon SC, Fang JW, Silverman AL et al:The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 32:400-404, 2000
PubMed
14) Lee SS, Sherman M:Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values. J Viral Hepat 8:202-205, 2001
PubMed
15) Di Bisceglie AM, Thompson J, Smith-Wilkaitis N et al:Combination of interferon and ribavirin in chronic hepatitis C:re-treatment of nonresponders to interferon. Hepatology 33:704-707, 2001
PubMed
16) Jacobson IM, Russo MW, Lebovics E et al:Interferon alfa-2 b and ribavirin for patients with chronic hepatitis C and normal ALT:final results. Gastroenterology 122 (abstract):A 627, 2002
 
17) Sponseller C, Koehler KM, Hoffman JA etal:Use of interferon α-2 b and ribavirin for treatment of patients with chronic hepatitis Cwith normal ALT levels. Hepatology 36 (abstract):579 A, 2002
 
18) Gonzalez HJ, Ho SB, Gross JB et al:Efficacy of daily induction dosing vs standard thrice weekly dosing of interferon-alpha 2 B for initial treatment of chronic hepatitis C. Dig Dis Sci 47:784-792, 2002
 
19) Heathcote EJ, Shiffman ML, Cooksley WG et al:Peginterferon alfa-2 a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343:1673-1680, 2000
PubMed
20) Shiratori Y, Moriyama M, Imazeki F et al:A prospective study of interferon therapy modified by pre-treatment viral load in cirrhotic patients. Liver 20:271-280, 2000
PubMed
21) Shinzawa H, Yoshida Y, Masamune O et al:Analysis of biochemical and virological efficacy of human lymphoblastoid interferon (IFN) in patients with compensated type Cliver cirrhosis:comparative study between increase in individual IFN dose and prolonging of treatment period, using a multicenter randomized controlled trial. Dig Dis Sci 45:575-580, 2000
 
22) Bernardinello E, Cavalletto L, Chemello L et al:Long-term clinical outcome after betainterferon therapy in cirrhotic patients with chronic hepatitis C. Hepatogastroenterology 46:3216-3222, 1999
PubMed
23) Camma C, Giunta M, Chemello L et al:Chronic hepatitis C:interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP) . Hepatology 30:801-807, 1999
PubMed
24) Schalm SW, Weiland O, Hansen BE et al:Interferon-ribavirin for chronic hepatitis C with and without cirrhosis:analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology 117:408-413, 1999
 
25) Everson GT, Jensen DM, Craig JR et al:Efficacy of interferon treatment for patients with chronic hepatitis C:comparison of response in cirrhotics, fibrotics, or nonfibrotics. Hepatology 30:271-276, 1999
PubMed
26) Valla DC, Chevallier M, Marcellin P et al:Treatment of hepatitis C virus-related cirrhosis:a randomized, controlled trial of interferon alfa-2 b versus no treatment. Hepatology 29:1870-1875, 1999
PubMed
27) Shiratori Y, Yokosuka O, Nakata R et al:Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology 29:1573-1580, 1999
PubMed
28) Hu KQ, Tong MJ:The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29:1311-1316, 1999
 
29) al-Faleh FZ, Sbeih F, al-Karawi M et al:Treatment of chronic hepatitis C genotype 4 with alpha-interferon in Saudi Arabia:a multicenter study. Hepatogastroenterology 45:488-491, 1998
PubMed
30) Kasahara A, Hayashi N, Mochizuki K et al:Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 27:1394-1402, 1998
PubMed
31) Davis GL, Esteban-Mur R, Rustgi V et al:Interferon alfa-2 b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339:1493-1499, 1998
PubMed
32) Fried MW, Shiffman ML, Reddy KR et al:Peginterferon alfa-2 a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982, 2002
PubMed
33) Poynard T, Marcellin P, Lee SS et al:Randomised trial of interferon alpha 2 b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2 b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432, 1998
 
34) Nishiguchi S, Kuroki T, Nakatani S et al:Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051-1055, 1995
PubMed
35) Kasahara A, Hayashi N, Mochizuki K et al:Pretreatment viral load and response to interferon therapy for liver cirrhosis caused by hepatitis C virus:a multicenter controlled study. Hepatol Res 16:124-138, 2000
 
36) McHutchison JG, Gordon SC, Schiff ER et al:Interferon alfa-2 b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485-1492, 1998
PubMed
37) Manns MP, McHutchison JG, Gordon SC et al:Peginterferon alfa-2 b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial. Lancet 358:958-965, 2001
 
38) Van Thiel DH, Friedlander L, Caraceni P et al:Treatment of hepatitis C virus in elderly persons with interferon alpha. J Gerontol A Biol Sci Med Sci 38:M 330-M 333, 1995
 
39) Horiike N, Masumoto T, Nakanishi K et al:Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol 10:246-249, 1995
 
40) Bresci G, Del Corso L, Romanelli AM et al:The use of recombinant interferon alfa-2 b in elderly patients with anti-HCV positive chronic active hepatitis. J Am Geriatr Soc 41:857-862, 1993
PubMed
P.241 掲載の参考文献
1) Farinati F, Cardin R, De Maria N et al:Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitiS. J Hepatol 22:449-456, 1995
PubMed
2) Bacon BR, Britton RS:The pathology of hepatic iron overload:a free radical-mediated process? Hepatology 11:127-137, 1990
PubMed
3) 斉藤浩之, 長谷部千登美, 高後裕:潟血療法が奏効したC型慢性肝炎の症例. 治療学 33:100-103, 1999
 
4) Hayashi H, Takikawa T, Nishimura N et al:Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 89:986-988, 1994
 
5) Hayashi H, Takikawa T, Nishimura N et al:Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 22:268-271, 1995
PubMed
6) Piperno A, Sampietro M, D:Alba R et al:Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 16:248-254, 1996
PubMed
7) Tsai NC, Zuckerman E, Han SH et al:Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenteron 92:1831-1834, 1997
PubMed
8) Fong TL Han SH, Tsai NC et al:A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J Hapatol 28:369-374, 1998
PubMed
9) Herrera JL:Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to interferon therapy. Am J Gastroenterol 94:3571-3575, 1999
 
10) Di Bisceglie AM, Bonkovsky HL, Chopra S et al:Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon:a multicenter, prospective, randomized, controlled trial. Hepatology 32:135-138, 2000
 
11) 斉藤浩之, 高後裕:C型肝炎のすべて, 治療:インターフェロン効果不十分例に対する対策, 潟血療法, 除鉄療法. 肝・胆・膵 43:973-982, 2001
 
12) Fargion S, Fracanzani AL, Rossini A et al:Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C:results of an Italian multicenter randomized study. Am J Gastroenterol 97:1204-1210, 2002
PubMed
13) Van Thiel DH, Friedlander L, Fagiuoli S et al:Response to interferon-alpha therapy is influenced by the iron content of the liver. J Hepatol 20:410-415, 1994
 
14) Olynyk JK, Reddy KR, Di Bisceglie AM et al:Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 108:1104-1109. 1995
PubMed
15) Banner BF, Barton AL, Cable EE et al:A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. Mod Pathol 8:232-238, 1995
PubMed
16) Arber N, Moshkowitz M, Konikoff F et al:Elevated serum iron predicts poor response to interferon treatment in patients with chronic HCV infection. Dig Dis Sci 40:2431-2433, 1995
PubMed
17) Barton AL, Banner BF, Cable EE et al:Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 103:419-424, 1995
PubMed
18) Izumi N, Enomoto N, Uchihara M et al:Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. Dig Dis Sci 41:989-994, 1996
PubMed
19) Clemente MG, Congia M, Lai ME et al:Effect of iron overload on the response to recombinant interferon-alpha treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 125:123-128, 1994
PubMed
20) Ikura Y, Morimoto H, Johmura H et al:Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 91:1367-1373, 1996
PubMed
21) Kaji K, Nakanuma Y, Harada K:Hemosiderin deposition in portal endothelial cells is a histologic marker predicting poor response to interferon-alpha therapy in chronic hepatitis C. Pathol Int 47:347-352, 1997
PubMed
22) Akiyoshi F, Sata M, Uchimura Y et al:Hepatic iron stainings in chronic hepatitis C patients with low HCV RNA levels:a predictive marker for IFN therapy. Am Gastroenterol 92:1463-1466, 1997
 
23) Ortiz V, Olaso V, Lopez Viedma B et al:The effect of iron depletion on the response to interferon treatment in patients with chronic hepatitis C. Pilot study. Gastroenterol Hepatol 22:122-126, 1999
PubMed
24) Guyader D, Boucher E, Andre P et al:A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon. Am J Gastroenterol 94:1696-1698, 1999
 
25) Yano M, Hayashi H, Wakusawa S:Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol 97:133-137, 2002
PubMed
26) Kato J, Kobune M, Kohgo Y et al:Hepatic iron deprivation prevents spontaneous development of fulminant hepatitis and liver cancer in Long-Evans Cinnamon rats. J Clin Invest 98:923-929, 1996
PubMed
27) Kato J, Kobune M, Nakamura T et al:Normalization of elevated hepatic 8-hydroxy-2:-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 61:8697-8702, 2001
PubMed
28) McKie AT, Barrow D, Latunde-Dada GO et al:An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291:1755-1759, 2001
PubMed
29) Kishi F, Tabuchi M:Complete nucleotide sequence of human NRAMP 2 cDNA. Mol Immunol 34:839-842, 1997
 
30) Donovan A, Brownlie A, Zhou Y et al:Positional cloning of zebrafish ferroportin 1 identifies a conserved vertebrate iron exporter. Nature 403:776-781, 2000
PubMed
31) 松本匡史, 今村重義, 佐藤仁美ほか:C型慢性肝炎に対する食事性の鉄摂取制限の有効性. 肝臓 40:436-444, 1999
 
32) 木村文昭, 川村望, 野口敏生ほか:鉄摂取制限療法でtransaminaseの良好なコントロールが可能であった慢性C型肝炎の5例. Progress in Medicine 19:1535-1537, 1999
Medical*Online
33) Tandon N, Thakur V, Guptan RK et al:Beneficial influence of an indigenous low-iron diet on serum indicators of iron status in patients with chronic liver disease. Br J Nutr 83:235-239, 2000
PubMed
P.248 掲載の参考文献
1) McHutchison JG, Gordon SC, Schiff ER et al:Interferon alfa-2 b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485-1492, 1998
PubMed
2) Davis GL, Esteban-Mur R, Rustgi V et al:Interferon alfa-2 b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339:1493-1499, 1998
PubMed
3) 飯野四郎, 松嶋喬, 熊田博光ほか:Genotype 1b かつ高ウイルス量のC型慢性肝炎に対するインターフェロンα-2bとSCH 18908 (リバビリン) の併用投与とインターフェロンα-2b単独投与との比較-二重盲検群間比較法を用いた用法・用量の比較. 臨医薬 18:565-591, 2002
 
4) 豊田成司, 妻神重彦, 安田清美ほか:インターフェロン無効または再燃したC型慢性肝炎に対するインターフェロンα-2bとSCH 18908 (リバビリン) の併用投与とインターフェロンα-2b単独投与との比較-二重盲検群間比較法を用いた併用効果の検討. 臨医薬 18:539-563, 2002
 
5) Kilham L, Ferm VH:Congenital anomalies induced in hamster embryos with ribavirin. Science 195:413-414, 1977
PubMed
6) Canonico PG, Kastello MD, Spears CT et al:Effects of ribavirin on red blood cells. Toxicol Appl Pharmacol 74:155-162, 1984
PubMed
7) Lau JY, Tam RC, Liang TJ et al:Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35:1002-1009, 2002
PubMed
8) Poynard T, McHutchison J, Manns M et al:Impact of pegylated interferon alfa-2 b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122:1303-1313, 2002
PubMed
9) Manns MP, McHutchison JG, Gordon SC et al Peginterferon alfa-2 b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomized trial. Lancet 358:958-965, 2001
 

PART 5 新しいアプローチによるC型慢性肝炎治療の今後

P.254 掲載の参考文献
1) McHutchison JG, Patel K:Future therapy of hepatitis C. Hepatology 36 (5suppl 1):S 245-S 252, 2002
 
2) Lurie Y, Nevens F, Aprosina ZG et al:A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydro-chloride and interferon-alpha-2 b for the treatment of chronic hepatitis C. J Viral Hepat 9:346-353, 2002
 
3) Arase Y, Ikeda K, Murashima N et al:The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79:1494-1500, 1997
 
4) Hayashi H, Takikawa T, Nishimura N etal:Improvement of serum aminotransferase levels after phlebotomy in patients withchronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 89:986-988, 1994
 
5) Kato J, Kobune M, Nakamura T et al:Normalization of elevated hepatic 8-hydroxy-2:-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 61:8697-8702, 2001
PubMed
6) Factor VM, Laskowska D, Jensen MR et al:Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model. Proc Natl Acad Sci USA 97:2196-2201, 2000
 
P.263 掲載の参考文献
1) Velculescu VE, Zhang L, Vogelstein B et al:Serial analysis of gene expression. Science 270:484-487, 1995
PubMed
2) Yamashita T, Hashimoto S, Kaneko S et al:Comprehensive gene expression profile of a normal human liver. Biochem Biophys Res Commun 269:110-116, 2000
PubMed
3) Yamashita T, Kaneko S, Hashimoto S et al:Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma. Biochem Biophys Res Commun 282:647-654, 2001
PubMed
4) Shirota Y, Kaneko S, Honda M et al:Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology 33:832-840, 2001
PubMed
5) Honda M, Kaneko S, Kawai H et al:Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 120:955-966, 2001
 
6) Kawai HF, Kaneko S, Honda M et al:alpha-fetoprotein-producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis. Hepatology 33:676-691, 2001
PubMed
7) Kurachi M, Hashimoto S, Obata A et al:Identification of 2, 3, 7, 8-tetrachlorodibenzop-dioxin-responsive genes in mouse liver by serial analysis of gene expression. Biochem Biophys Res Commun 292:368-377, 2002
 
P.271 掲載の参考文献
1) Uze G, Lutfalla G, Gresser I:Genetic transfer of a functional human interferon alphareceptor into mouse cells:cloning and expression of its cDNA. Cell 60:225-234, 1990
 
2) Novick D, Cohen B, Rubinstein M:Soluble interferon-alpha receptor molecules are present in body fluids. FEBS lett 314:445-448, 1992
PubMed
3) Novick D, Cohen B, Rubinstein M:The human interferon alpha/beta receptor:characterization and molecular cloning. Cell 77:391-400, 1994
PubMed
4) Callard RE, Gearing AJH:IFNα. In:The cytokine facts book, Academic press, London, 1994, P. 151
 
5) Domanski P, Witte M, Kellum M et al:Cloning and expression of a long form of the beta subunit of the interferon alpha-beta receptor that is required for signaling. J Biol Chem 270:21606-21611, 1995
PubMed
6) Pfeffer LM, Basu L, Pfeffer SR et al:The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action. J Biol Chem 272:11002-11005, 1997
PubMed
7) Rose-John S, Heinrich PC:Soluble receptors for cytokines and growth factors:generation and biological function. Biochem J 300:281-290, 1994
PubMed
8) Mizukoshi E, Kaneko S, Kaji K et al:Serum levels of soluble interferon Alfa/Beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C. Hepatology 30:1325-1331, 1999
 
9) Han CS, Chen Y, Ezashi T et al:Antiviral activities of the soluble extracellular domains of type I interferon receptors. Proc Natl Acad Sci USA 98:6138-6143, 2001
PubMed
10) Fukuda R, Ishimura N, Kushiyama Y et al:Effectiveness of interferon-alpha therapy inchronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J Hepatol 26:455-461, 1997
 
11) Yatsuhashi H, Yamasaki K, Aritomi T et al:Quantitative analysis of interferon alpha/beta receptor mRNA in the liver ofpatients with chronic hepatitis C:correlation with serum hepatitis C virus-RNA levels and response to treatment with interferon. J Gastroentero Hepatol 12:460-467, 1997
 
12) Mizukoshi E, Kaneko S, Yanagi M et al:Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients. J Med Virol 56:217-223, 1998
PubMed
13) Morita K, Tanaka K, Saito S et al:Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C. J Med Virol 58:359-365, 1999
PubMed
14) Yatsuhashi H, Fujino T, Matsumoto T et al:Immunohistochemical analysis of hepatic interferon alpha-beta receptor level:relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C. J Hepatol 30:995-1003, 1999
PubMed
15) David M:Signal transduction by type I interferons. Biotechniques (suppl):58-65, 2002
PubMed
16) Borden EC:Gene regulation and clinical roles for interferons in neoplastic diseases. Oncologist 3:198-203, 1998
PubMed
17) Harada H, Taniguchi T, Tanaka N:The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie 80:641-650, 1998
PubMed
18) Yasukawa H, Misawa H, Sakamoto H et al:The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 18:1309-1320, 1999
PubMed
19) Tamura T, Matsuzaki M, Harada H et al:Upregulation of interferon-alpha receptor expression in hydroxyurea-treated leukemia cell lines. J Investig Med 45:160-167. 1997
PubMed
20) Martin JH, McKibben BM, Lynch M et al:Modulation by oestrogen and progestins/antiprogestins of alpha interferon receptor expression in human breast cancer cells. Eur J cancer 27:143-146, 1991
PubMed
P.279 掲載の参考文献
1) Matsushita M, Hijikata M, Matsushita M et al:Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients. J Hepatol 29:695-700, 1998
PubMed
2) Hijikata M, Mishiro S, Miyamoto C et al:Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients:revisited by analyzing two SNP sites (-123 and-88) in vivo and in vitro. Intervirology 44:379-382, 2001
PubMed
3) Matsuyama N, Mishiro S, Sugimoto M et al:The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 25:221-225, 2003
PubMed
4) Promrat K, McDermott DH, Gonzalez CM et al:Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 124:352-360, 2003
PubMed
P.286 掲載の参考文献
1) Fried MW, Shifflnan ML, Reddy KR et al:Peginterferon alfa-2 a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 347:975-982, 2002
 
2) Kamal SM, Fehr J, Roesler B et al:Peginterferon alone or with ribavirin enhances HCV-specific CD 4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 123:1070-1083, 2002
PubMed
3) Banchereau J, Briere F, Caux C et al:Immunobiology of dendritic cells. Annu Rev Immunol 18:767-811, 2000
PubMed
4) Liu YJ:Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106:259-262, 2001
PubMed
5) Dieu-Nosjean MC, Vicari A, Lebecque S et al:Regulation of dendritic cell trafficking:a process that involves the participation of selective chemokines. J Leukoc Biol 66:252-262, 1999
PubMed
6) Kanto T, Hayashi N, Takehara T et al:Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 162:5584-5591, 1999
PubMed
7) Matsuura Y, Tani H, Suzuki K et al:Characterization of pseudotype VSV possessing HCV envelope proteins. Virology 286:263-275, 2001
PubMed

書評

最近チェックした商品履歴

Loading...